- Home
- SXTP vs ONCO Comparison
SXTP vs ONCO Comparison
Compare SXTP & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SXTP | ONCO |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.0M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SXTP | ONCO |
|---|---|---|
| Price | $0.90 | $0.48 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.70 | N/A |
| AVG Volume (30 Days) | 126.3K | ★ 6.4M |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.77 | 22.80 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,005,471.00 | $815,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 65.49 | N/A |
| 52 Week Low | $0.34 | $0.09 |
| 52 Week High | $8.62 | $798.00 |
Technical Indicators
Market Signals| Indicator | SXTP | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 36.73 | 34.16 |
| Support Level | $0.84 | $0.09 |
| Resistance Level | $1.63 | $1.02 |
| Average True Range (ATR) | 0.14 | 0.09 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 2.63 | 1.86 |
Price Performance
Historical ComparisonAbout SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.